Myriad Genetics reported first-quarter results with revenue rising slightly year over year, but losses widened versus the prior period. The report points to modest top-line growth but deteriorating profitability, a mildly negative mix for the stock. The update is likely to be notable for MYGN shares but is not a broader market driver.
Myriad Genetics reported first-quarter results with revenue rising slightly year over year, but losses widened versus the prior period. The report points to modest top-line growth but deteriorating profitability, a mildly negative mix for the stock. The update is likely to be notable for MYGN shares but is not a broader market driver.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
